



Kane Biotech Inc.

Symbol: TSXV: KNE | OTC: KNBIF

Sector: Biotech

Purpose: Raise Awareness / Open Market Buying

Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of products that prevent and remove microbial biofilms. When protected by a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides and host immune responses. This resiliency contributes to numerous human health related problems with an addressable market of over \$340 million USD in the US alone (Grandview Research). Kane Biotech's mission is to commercialize within Canada and the US through distribution networks with an eye to licensing its to global industry players. Kane Biotech's lead products are (Rrevyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Spray which have been cleared by the US FDA and approved by Health Canada. The Company has 10 employees and is headquartered in Winnipeg, Manitoba, Canada.

Investor Bullet Points:

- US FDA cleared revyve Wound Gel in 2024, revyve Wound Spray in 2025, revyve Wound Cleanser in 2026
- Real World Evidence trials in 2025 and 2026, with data reported at major medical meetings
- Restarted distribution in US and Canada in 2026, with experienced commercial team members
- Anticipated EBITDA positive mid 2027.

Robert Huizinga – Interim CEO

Dr. Robert Huizinga co-founded Aurinia Pharmaceuticals Inc. in Victoria Canada (\$AUPH) which went from \$10 million to a peak valuation of >\$4 billion USD. He led the Phase I-III development of voclosporin for lupus nephritis. During his time at pharma, Dr. Huizinga has raised over \$500 million USD on the public stock markets, has

presented and defended data to the FDA, EMA, Health Canada, PMDA, BfArM, and the Japanese regulator (PMDA). He saw voclosporin through the first-year commercialization with sales >\$100 million USD, and now is a consultant to various companies as well filling the role as Interim CEO of Kane Biotech Inc. in Canada.